9 juin 2017

New data and analyses of our diabetes portfolio and PCSK9 inhibitor (only in English)

More than 80 Sanofi Diabetes and Cardiovascular-related contributions

 

New data and analyses of our diabetes portfolio and PCSK9 inhibitor (only in English)
More than 80 Sanofi Diabetes and Cardiovascular-related contributions

At the American Diabetes Association (ADA) 77th Scientific Sessions, one of the world’s largest diabetes meetings, the presentation of the latest scientific findings related to our portfolio will highlight Sanofi’s commitment to innovation through providing a variety of solutions that can deliver cost-effective, personalized and outcomes-driven care.

ADA 2017 will feature more than 80 Sanofi Diabetes and Cardiovascular-related contributions, including abstracts, symposia and product theaters, in which new data and analyses will explore unmet needs and how these are addressed by our marketed and pipeline products.

We invite journalists from outside of the United States to use the materials posted on this page to inform and enhance their reporting related to our products.


Media Information to download: